P2 A single monotherapy dose of MK-8591, a novel NRTI, suppresses HIV for 10 days

• Martine Robberechts,
• Evan J. Friedman,
• Dirk Schürmann,
• Deanne Jackson Rudd,
• Inge De Lepeleire,
• Sabrina Fox-Bosetti,
• Sandra Zhang,
• Andreas Huser,
• Daria Hazuda,
• Marian Iwamoto,
• JayA Grobler

Affiliations

Martine Robberechts

MSD (Europe) Inc., Brussels, Belgium

Evan J. Friedman

Merck & Co., Inc. Kenilworth, NJ, USA

Dirk Schürmann

Charité Universitätsmedizin Berlin

Deanne Jackson Rudd

Merck & Co., Inc. Kenilworth, NJ, USA

Inge De Lepeleire

MSD (Europe) Inc., Brussels, Belgium

Sabrina Fox-Bosetti

Merck & Co., Inc. Kenilworth, NJ, USA

Sandra Zhang

Merck & Co., Inc. Kenilworth, NJ, USA

Andreas Huser

Charité Research Organisation, Berlin, Germany

Daria Hazuda

Merck & Co., Inc. Kenilworth, NJ, USA

Marian Iwamoto

Merck & Co., Inc. Kenilworth, NJ, USA

JayA Grobler

Merck & Co., Inc. Kenilworth, NJ, USA